The Controlled Substances Act leaves pathway for intoxicating hemp-derived cannabinoids

Delta-8 THC exploded onto the scene in 2019, followed by delta-10 THC, THC-O acetate and HHC in 2020 and 2021.

While state regulatory agencies have opted for a whack-a-mole approach that focuses on controlling one cannabinoid at a time, the federal government has been largely silent on the legal status of hemp-derived cannabinoids.

Marijuana products technically aren’t eligible for federal trademarks because the plant is illegal under the Controlled Substances Act

Marijuana products technically aren’t eligible for federal trademarks because the plant is illegal under the Controlled Substances Act.

But that doesn’t mean cannabis businesses can’t protect their intellectual property and build brand awareness through patents and federal trademarks—the latter is applicable if the application doesn’t involve a plant-touching side of the business.

US Supreme Court rejects challenge to Mississippi’s marijuana advertising ban

Advertisements by state-licensed medical marijuana businesses in Mississippi don’t enjoy First Amendment free-speech protections.

How to manage the challenges of cannabis advertising restrictions

For cannabis business owners, advertising their products presents unique challenges.

Marijuana rescheduling will be among DEA nominee’s ‘priorities’ but …

President Donald Trump’s nominee to head the U.S. Drug Enforcement Administration told a Senate committee that reviewing the agency’s administrative process to reclassify marijuana will be “one of my first priorities” if he is confirmed.

Doctors who support marijuana rescheduling drop lawsuit against DEA

A group of medical professionals who support rescheduling marijuana have dropped a lawsuit against the U.S. Drug Enforcement Administration that, among other things, accused the agency of rigging the process against changing the drug’s status under federal law.

Rescheduling or descheduling marijuana: How would industry be impacted?

The possible reclassification of marijuana under the federal Controlled Substances Act is sparking debate about dismantling barriers to interstate commerce and the future of the industry.

Congressional bills would provide federal marijuana tax relief, limited descheduling

If Congress can’t – or won’t – legalize marijuana at the federal level, the least U.S. lawmakers can do is get out of the way of states with adult-use cannabis.

No progress at DEA on marijuana rescheduling, new filing says

The U.S. Drug Enforcement Administration’s marijuana rescheduling process “remains pending,” according to a new filing.

Will marijuana rescheduling happen under Trump? Industry’s doubts grow

President Donald Trump’s choices over his first 50 days in office, including appointments to lead the federal drug and health agencies, are sowing serious doubts that marijuana’s status under federal law will change anytime soon.

Dear Congress: 280E isn’t a tax break for cannabis companies

Because 280E thwarts operational success, it greatly incentivizes people to perpetuate the illicit marijuana market.